Ciba-geigy Corporation

Ucp Gen-pharma Ag

Sefik Alkan

Francois Meyer

Jutta Heim

Bernd Meyhack

Markus G Grutter

Bhabatosh Chaudhuri

Jan Van Oostrum

Albert Hinnen

Fredericus A Asselbergs

Andreas Meister

Bhanu Rajput

Hans Rink

Peter Sieber

Hans Fritz

Werner Rittel

Manfred Liersch

Christoph Heusser

Walter M&auml;rki

Rudolf H Andreatta

Jeanette Wood

Ursula Seem&uuml;ller

The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.

Process for preparing recombinant eglin, protease inhibitor

Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.

Hybrid plasminogen activator

DNA molecules encoding hybrid proteins of tissue plasminogen activator

Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.

Hybrid interferons

The invention relates to novel monoclonal antibodies having a high affinity for human renin, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, and to processes for the preparation of said hybridoma cells lines. The monoclonal antibodies according to the invention and their derivatives can be used for the qualitative and quantitative determination of human renin and structurally similar renin, for the purification of human renin and structurally similar renin and for the treatment of high blood pressure and cardiac insufficiency.

Novel monoclonal antibodies to human renin and hybridoma cells,

Growing community of inventors

Riehen, Switzerland

Sefik Alkan